Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xvivo Perfusion AB ( (SE:XVIVO) ) has issued an update.
Xvivo Perfusion reported first-quarter 2026 net sales of SEK 241 million, a 10 percent increase in SEK, with 23 percent organic growth in local currencies and strong momentum in thoracic and abdominal product segments. Profitability improved with higher EBITDA and net profit, supported by solid cash flow from operations despite continued R&D investments and service revenue softness, while new clinical heart trial results and follow-up data reinforced the company’s position in advanced heart preservation and its long-term growth ambitions in transplant care.
The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK225.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
Xvivo Perfusion AB is a Swedish medical technology company focused on advanced organ preservation and perfusion systems for thoracic and abdominal transplantation. Its products and services target transplant centers globally, aiming to improve organ quality and increase the number of viable organs for patients awaiting transplants.
Average Trading Volume: 150,948
Technical Sentiment Signal: Buy
Current Market Cap: SEK9.61B
See more insights into XVIVO stock on TipRanks’ Stock Analysis page.